N4-Hydroxycytidine Derivatives Broad-Spectrum Antiviral Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for new compounds and treatments for viral infections, particularly for vector-borne viruses like Eastern, Western, and Venezuelan Equine Encephalitis, Chikungunya fever, Ebola, Influenza, RSV, and Zika virus infections.
Innovation Solution
The development of N4-hydroxycytidine and its derivatives, which are used in pharmaceutical compositions for treating or preventing viral infections. These compounds can be administered in various forms, including tablets, capsules, pills, or as an aerosol, and are designed to increase bioavailability and effectiveness against a range of viral pathogens.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If conventional antiviral treatments are used for vector-borne viruses, then existing treatment protocols can be applied, but there is a lack of effective treatments for emerging viral infections
Solution Approach 1:
The patent applies universality by developing N4-hydroxycytidine and its derivatives as broad-spectrum antiviral agents effective against multiple virus families including Togaviridae, Paramyxoviridae, Orthomyxoviridae, and Flaviviridae. The compound serves multiple functions by targeting different viral pathogens with a single agent, eliminating the need for virus-specific treatments and providing reliable therapeutic coverage for emerging infections
Solution Approach 2:
The patent employs parameter changes by modifying the chemical structure of cytidine through N4-hydroxylation and various substitutions at positions R1-R9 to optimize antiviral activity. These structural parameter changes enhance the compound's ability to inhibit viral replication while improving pharmacokinetic properties, thereby resolving the contradiction between versatility and reliability
2Reliability
If N4-hydroxycytidine and derivatives are administered to treat viral infections, then viral loads are reduced and survival rates improve, but the compounds require optimization for bioavailability and administration
Solution Approach 1:
The patent applies parameter changes by systematically modifying physical and chemical properties of N4-hydroxycytidine derivatives, including solubility, stability, and molecular structure, to optimize oral bioavailability and enable various administration routes. These parameter optimizations transform the compound from a research molecule into a clinically viable treatment
Solution Approach 2:
The patent uses prodrugs as intermediaries to improve bioavailability. The prodrug form facilitates better absorption and distribution, then converts to the active N4-hydroxycytidine compound in vivo, thereby resolving administration challenges while maintaining therapeutic effectiveness
Data Source
AI summary
This disclosure relates to certain N4-hydroxycytidine derivatives, pharmaceutical compositions, and methods related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of viral infections, such as Eastern, Western, and Venezuelan Equine Encephalitis (EEE, WEE and VEE, respectively), Chikungunya fever (CHIK), Ebola, Influenza, RSV, and Zika virus infection with the disclosed compounds.